Triazole Derivatives Selective Gamma-Secretase Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease, such as blocking β-amyloid peptide production, can lead to undesirable side effects due to the involvement of β-amyloid in physiological processes and the action of γ-secretase on multiple substrates, necessitating a method that selectively attenuates Aβ(1-42 production without suppressing shorter chain isoforms.
Innovation Solution
Development of triazole derivatives that modulate γ-secretase activity to selectively reduce Aβ(1-42 production, thereby reducing neurotoxicity and facilitating easier clearance from the brain, without significantly lowering production of less neurotoxic Aβ(1-40) isoforms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If γ-secretase is inhibited to block Aβ production, then Aβ production is reduced, but unwanted side effects occur due to γ-secretase acting on multiple substrates
Solution Approach 1:
The patent applies local quality by creating selective inhibition of γ-secretase for specific substrates. The compound selectively attenuates Aβ(1-42) production while preserving shorter chain isoforms and other γ-secretase substrates like Notch. This substrate-specific selectivity is achieved through the unique molecular structure of the triazole derivative that interacts differentially with various γ-secretase substrates, thereby reducing harmful side effects while maintaining therapeutic effect.
Solution Approach 2:
The patent utilizes parameter changes by modulating the catalytic parameters of γ-secretase rather than completely inhibiting it. The compound changes the substrate preference and catalytic efficiency parameters of γ-secretase, shifting the production profile toward shorter chain Aβ isoforms while maintaining overall enzyme activity. This partial modulation approach preserves physiological functions while reducing pathogenic Aβ(1-42) production.
2Quantity of substance
If complete suppression of Aβ production is achieved, then plaque formation is reduced, but physiological functions dependent on Aβ are compromised
Solution Approach 1:
The patent applies partial action by achieving selective attenuation rather than complete suppression of Aβ production. The compound reduces Aβ(1-42) production by approximately 50-70% in vitro, but this partial inhibition is sufficient to reduce neurotoxicity and plaque formation while leaving shorter chain isoforms intact. This partial modulation approach maintains physiological functions that require Aβ while eliminating the harmful effects of long chain Aβ(1-42).
Data Source
AI summary
According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions.